BFA
GEVA

BlackRock Fund Advisors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

BlackRock Fund Advisors’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,058,768
Closed -$103M – 3967
2015
Q1 		$103M Buy
1,058,768
+119,422
+13% +$12.6M 0.02% 970
2014
Q4 		$87.2M Buy
939,346
+70,643
+8% +$5.57M 0.02% 1051
2014
Q3 		$59.7M Buy
868,703
+2,392
+0.3% +$171K 0.02% 1241
2014
Q2 		$90.8M Sell
866,311
-31,045
-3% -$2.64M 0.03% 952
2014
Q1 		$74.5M Buy
897,356
+65,335
+8% +$6.04M 0.02% 1089
2013
Q4 		$53.8M Buy
832,021
+87,843
+12% +$5.21M 0.02% 1346
2013
Q3 		$47.2M Buy
744,178
+103,080
+16% +$5.07M 0.02% 1383
2013
Q2 		$26.9M Buy
+641,098
New +$29.2M 0.01% 1633

BlackRock Fund Advisors's GEVA Position: Q2 2015 in Review

BlackRock Fund Advisors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 1,058,768 shares — an estimated $103M sold.

BlackRock Fund Advisors first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $103M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • BlackRock Fund Advisors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • BlackRock Fund Advisors sold 1,058,768 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $103M.
  • BlackRock Fund Advisors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • BlackRock Fund Advisors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $103M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on BlackRock Fund Advisors's 13F filing for Q2 2015, filed 7 Aug 2015.